Combined intra-arterial and systemic chemotherapy for recurrent malignant brain tumors.

Seventy-nine patients harboring recurrent brain tumors received four cycles of infraophthalmic carotid injections of 160 mg of carmustine. Two milligrams of intravenous vincristine and 50 mg of oral procarbazine was also administered three times daily for 1 week in conjunction with each BCNU treatment. The response rate was 60% with a median survival for patients with astrocytomas, anaplastic astrocytomas, and glioblastomas of 32, 20, and 6.5 months, respectively. The median survival of the responding patients was 20 months, and the survival at 30 months was 45%. The survival in patients not responding to treatment was 5 months, reflecting the natural history of the tumor. There have been no deaths related to the treatment procedure. No incidents of severe or permanent eye complications or leukoencephalopathy were observed. Based on multivariate survival analysis, only patients with a good performance status who are not steroid dependent are candidates for this treatment.

[1]  W. P. Dixon,et al.  BMPD statistical software manual , 1988 .

[2]  S. Steinberg,et al.  Low-grade astrocytomas: treatment results and prognostic variables. , 1987, International journal of radiation oncology, biology, physics.

[3]  M. Ammirati,et al.  Reoperation in the treatment of recurrent intracranial malignant gliomas. , 1987, Neurosurgery.

[4]  W. Shapiro.  Therapy of adult malignant brain tumors: what have the clinical trials taught us? , 1986, Seminars in oncology.

[5]  J. Doppman,et al.  Arterial drug infusion with extracorporeal removal. II. Internal carotid carmustine in the rhesus monkey. , 1985, Cancer treatment reports.

[6]  L. Junck,et al.  Intra-arterial BCNU chemotherapy for treatment of malignant gliomas of the central nervous system. , 1984, Journal of neurosurgery.

[7]  S. Handel,et al.  Intracarotid infusion of cis‐diamminedichloroplatinum in the treatment of recurrent malignant brain tumors , 1984, Cancer.

[8]  C. West,et al.  Intraarterial 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and systemic chemotherapy for malignant gliomas: a follow-up study. , 1983, Neurosurgery.

[9]  U. Bogdahn.  Chemosensitivity of malignant human brain tumors , 1983, Journal of neuro-oncology.

[10]  D P Byar,et al.  Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. , 1983, Cancer treatment reports.

[11]  E. Freireich,et al.  Phase I study of aziridinylbenzoquinone (NSC 182986). , 1981, Cancer clinical trials.

[12]  F. Hochberg,et al.  Quality and duration of survival in glioblastoma multiforme. Combined surgical, radiation, and lomustine therapy. , 1979, JAMA.

[13]  B. Scheithauer.  Symptomatic subependymoma. Report of 21 cases with review of the literature. , 1978, Journal of neurosurgery.

[14]  V. Levin,et al.  Chemotherapy of recurrent medulloblastoma with combined procarbazine, CCNU, and vincristine. , 1978, Journal of neurosurgery.

[15]  Fenstermacher Jd,et al.  Theoretic limitations of intracarotid infusions in brain tumor chemotherapy. , 1977 .

[16]  D. Rall,et al.  Brain-tumor chemotherapy. Pharmacological principles derived from a monkey brain-tumor model. , 1977, Journal of neurosurgery.

[17]  M. Pike,et al.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.

[18]  P. Band,et al.  Radiotherapy and CCNU in the treatment of high-grade supratentorial astrocytomas. , 1976, Journal of neurosurgery.

[19]  W. Shapiro,et al.  Treatment of malignant glioma. A controlled study of chemotherapy and irradiation. , 1976, Archives of neurology.

[20]  Oldendorf Wh.  A comparison of carotid and venous injection of antitumor agent BCNU. , 1975 .

[21]  D. Cox.  Regression Models and Life-Tables , 1972 .

[22]  E. Hitchcock,et al.  TREATMENT OF MALIGNANT GLIOMATA. , 1964, Journal of neurosurgery.

[23]  F. Ederer,et al.  Maximum utilization of the life table method in analyzing survival. , 1958, Journal of chronic diseases.